Cardiac indicators are used to diagnose and risk stratify patients with chest discomfort and suspected acute coronary syndrome (ACS), as well as to treat and predict outcomes in patients with acute heart failure, pulmonary embolism, and other diseases.
A Cardiac Biomarkers Market is a protein-based molecule that may be quantified for heart disease prognosis and diagnosis. When the heart is injured or stressed, such as from a lack of oxygen, cardiac biomarkers are released into the bloodstream. Cardiovascular biomarkers including cardiac troponin, creatinine kinase, myoglobin, and others are used to diagnose disorders like ACS and heart ischemia.
ACS is caused by plaque formation in the arteries, which causes the arterial walls to narrow. When a plaque ruptures, the volume of oxygenated blood reaching the heart drops dramatically. Long-term chest pain is caused by a lack of blood supply. Cardiac Biomarkers Market ischemia, on the other hand, affects the ability of the heart muscles to pump enough blood to meet the needs of the heart cells. Shortness of breath, chest pain, sweating, and other symptoms are caused by a reduction in blood flow. Heart cells might die if their blood supply is cut off for an extended period of time. Acute myocardial infarction (AMI) or heart attack is the medical term for this ailment. Arrhythmia, or irregular cardiac contractions, can be fatal if permanent damage to the heart muscles occurs. A cardiac biomarker is an important tool for detecting and evaluating the occurrence of ACS or myocardial ischemia in individuals.
Over the forecast period, the rising prevalence of cardiovascular illnesses is expected to be the primary driver driving market growth.
Over the forecast period, the worldwide cardiac biomarkers market is expected to rise due to an increase in the number of individuals suffering from cardiovascular disease. According to the American College of Cardiology Foundation, roughly 1.05 million persons in the United States suffered from coronary artery disease in 2019. Furthermore, the Centers for Disease Control and Prevention (CDC) report 2020 estimates that roughly 805,000 Americans experience a heart attack each year.
Players to Watch
Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA are among the major competitors in the worldwide cardiac biomarker market.
Source Link:https://bit.ly/3yATzJO
0 Comments